In recent years, novel immunotherapies represented by programmed cell death-1/programmed cell death-ligand (PD-1/PD-L1) inhibitors have rapidly emerged in the field of PRAD treatment (8), and their efficacy largely depends on interactions with the tumor microenvironment (TME) (9, 10). Here, PDCD1 is linked to neoplasm.